Measurement of soluble fibrin monomer-fibrinogen complex in plasmas derived from patients with various underlying clinical situations.
We previously reported a monoclonal antibody named IF-43 that specifically recognizes thrombin-modified fibrinogen (desAA- and desAABB- fibrin monomer) bound with fibrinogen or other D(1) domain-containing plasmic fragments such as fragments X,Y, and D(1), but not intact fibrinogen or cross-linked fibrin degradation products (XDP). Here, we tentatively named such complexes, soluble fibrin monomer (FM) -fibrinogen complex. By utilizing IF-43, we have developed a kit to measure soluble FM-fibrinogen complex and compared the profiles with those of two established molecular markers for thrombo-embolic disorders: i.e. the thrombin-antithrombin complex (TAT) and the D-dimer in plasma of patients who underwent surgery without any thrombo-embolic complications. The result indicated that soluble FM-fibrinogen complex is a distinct entity from the two established molecular markers. We have also attempted to observe their profiles in patients with the disseminated intravascular coagulation syndrome (DIC). Although the pro-files of soluble FM-fibrinogen complex in individual patients appeared to vary from one patient to the other, the plasma level of soluble FM-fibrinogen complex was found to be increased at the initial phase of disseminated intravascular coagulation syndrome. Thus, the soluble FM-fibrinogen complex may serve as an independent molecular marker for the detection of thrombin generation and the diagnosis of thrombosis. The soluble FM-fibrinogen complex may also serve as a risk factor for thrombosis, because it may precipitate as insoluble complexes beyond its threshold in plasma, or when it is modified by thrombin.
Nakahara
Kunihiko
K
Iatron Laboratories, Inc., 1460-6 Mitodai, Mito, Tako-machi, Katori-gun, Chiba 289-2247, Japan. nakahara@iatron.co.jp
Kazahaya
Yumiko
Y
Shintani
Yuichi
Y
Yamazumi
Kensuke
K
Eguchi
Yutaka
Y
Koga
Shin
S
Wada
Hideo
H
Matsuda
Michio
M
D000990:Antithrombin III; D015415:Biomarkers / Q000097:blood; D004211:Disseminated Intravascular Coagulation / Q000097:blood*; D005337:Fibrin / Q000032:analysis / Q000378:metabolism*; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis / Q000378:metabolism*; D006801:Humans; D007841:Latex Fixation Tests; D010447:Peptide Hydrolases / Q000097:blood; D010949:Plasma / Q000737:chemistry; D011485:Protein Binding; D012307:Risk Factors; D012995:Solubility; D013927:Thrombosis / Q000175:diagnosis
D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; D000990:Antithrombin III; D005337:Fibrin; D005340:Fibrinogen; D010447:Peptide Hydrolases